查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1618144

气体交换肺功能测试市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032 年

Gas Exchange Pulmonary Function Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球气体交换肺功能测试市场价值达到2.385 亿美元，预计2024 年至2032 年复合年增长率将稳定在5.8%。和治疗疾病。透过评估扩散能力，气体交换测试提供了肺功能的重要见解，有助于制定客製化的治疗策略和有效的疾病管理。旨在增强呼吸系统健康的政府措施不断增多，正在显着推动市场成长。专注于呼吸系统疾病预防的政策，加上对早期检测和预防性医疗保健的日益重视，将气体交换肺部测试定位为呼吸系统健康管理的重要工具。

市场分为便携式和固定式系统，便携式设备预计将以6% 的复合年增长率增长，到2032 年将超过3.29 亿美元。 ，刺激了对便携式设备的需求测试解决方案。便携式设备可以在传统医疗机构之外进行测试，提高患者的便利性，并使医疗保健提供者在各种环境下具有更大的适应性。技术进步进一步推动了便携式肺功能测试 (PFT) 设备的采用，提高了准确性和易用性。就测试方法而言，市场分为气体扩散测试和心肺运动测试（CPET）。

气体扩散测试领域在 2023 年占据主导地位，占 61.2% 的市场份额，这得益于其在影响肺泡毛细血管膜上氧气和二氧化碳交换的条件下诊断和追踪肺功能的有效性。这种方法对于检测早期肺损伤至关重要，对于慢性呼吸道疾病患者至关重要。气体扩散测试提供有关肺部效率的精确资料，以管理损害呼吸功能的疾病。北美市场到2023 年将产生9,650 万美元的收入，预计到2032 年将保持复合年增长率5.2% 的增长。的治疗结果并减少再入院率。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 2.385 亿美元
预测值 3.92 亿美元
复合年增长率 5.8%

促进定期监测慢性肺部疾病的医疗保健政策推动了对肺功能检测的需求。此外，医疗保健行业向基于价值的护理的转变强调预防措施，并支持常规肺功能评估。对主动呼吸护理的日益关注加强了北美作为市场扩张主要贡献者的作用。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 呼吸道疾病盛行率上升
      • 技术进步
      • 扩大新兴市场的医疗保健基础设施
    • 产业陷阱与挑战
      • 设备成本高
  • 成长潜力分析
  • 监管环境
  • 报销场景
  • 技术景观
  • 差距分析
  • 波特的分析
  • PESTEL分析
  • 价值链分析
  • 未来市场趋势

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按系统类型，2021 - 2032 年

  • 主要趋势
  • 便携的
  • 固定式

第 6 章：市场估计与预测：按测试方法，2021 - 2032 年

  • 主要趋势
  • 气体扩散测试
  • 心肺运动试验（CPET）

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 慢性阻塞性肺病（COPD）
  • 气喘
  • 慢性呼吸短促
  • 肺纤维化
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断中心
  • 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • CHEST
  • COSMED
  • ECO MEDICS
  • Geratherm Medical
  • KoKo PFT
  • Koninklijke Philips
  • MGC Diagnostics Corporation
  • ndd Medical Technologies
  • PulmOne
  • SCHILLER
  • Vitalograph
  • Vyaire Medical
简介目录
Product Code: 11737

The Global Gas Exchange Pulmonary Function Testing Market reached a value of USD 238.5 million in 2023, with projections for a steady 5.8% CAGR from 2024 to 2032. This market primarily evaluates lung efficiency in transferring oxygen to the bloodstream and expelling carbon dioxide to diagnose and manage respiratory conditions like COPD and asthma. By assessing diffusion capacity, gas exchange testing provides critical insights into lung function, aiding in tailored treatment strategies and effective disease management. Increasing government initiatives aimed at enhancing respiratory health are significantly driving market growth. Policies focused on respiratory disease prevention, coupled with a rising emphasis on early detection and preventive healthcare, are positioning gas exchange pulmonary testing as a vital tool in respiratory health management.

The market is divided into portable and stationary systems, with portable devices projected to grow at a 6% CAGR and surpass USD 329 million by 2032. The need for flexible and accessible diagnostics, particularly with the rise in respiratory diseases, has fueled demand for portable testing solutions. Portable devices enable testing outside traditional healthcare facilities, improving patient convenience and allowing healthcare providers greater adaptability in various settings. Advances in technology have further boosted the adoption of portable pulmonary function test (PFT) devices, facilitating enhanced accuracy and ease of use. In terms of test methods, the market is segmented into gas diffusion tests and cardiopulmonary exercise testing (CPET).

The gas diffusion test segment dominated with a 61.2% market share in 2023, driven by its effectiveness in diagnosing and tracking lung function in conditions that impact oxygen and carbon dioxide exchange across the alveolar-capillary membrane. This method is crucial for detecting early lung damage, proving essential for patients with chronic respiratory diseases. Gas diffusion tests provide precise data on lung efficiency for managing diseases that impair respiratory function. The North American market, generating USD 96.5 million in revenue in 2023, is expected to maintain growth with a 5.2% CAGR through 2032. Regional growth is supported by government-led initiatives to improve outcomes for patients with respiratory conditions and reduce hospital readmissions.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$238.5 Million
Forecast Value$392 Million
CAGR5.8%

Healthcare policies promoting regular monitoring for chronic lung diseases drive the demand for pulmonary function testing. Furthermore, the healthcare industry's shift towards value-based care emphasizes preventive measures, supporting routine lung function assessments. This growing focus on proactive respiratory care reinforces North America's role as a major contributor to the market's expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of respiratory diseases
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Expansion of healthcare infrastructure in emerging markets
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost associated with equipment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Reimbursement scenario
  • 3.6 Technology landscape
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Value chain analysis
  • 3.11 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By System Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Portable
  • 5.3 Stationary

Chapter 6 Market Estimates and Forecast, By Test Method, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Gas diffusion tests
  • 6.3 Cardiopulmonary exercise testing (CPET)

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Chronic obstructive pulmonary disease (COPD)
  • 7.3 Asthma
  • 7.4 Chronic shortness of breath
  • 7.5 Pulmonary fibrosis
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals & clinics
  • 8.3 Diagnostic centers
  • 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 CHEST
  • 10.2 COSMED
  • 10.3 ECO MEDICS
  • 10.4 Geratherm Medical
  • 10.5 KoKo PFT
  • 10.6 Koninklijke Philips
  • 10.7 MGC Diagnostics Corporation
  • 10.8 ndd Medical Technologies
  • 10.9 PulmOne
  • 10.10 SCHILLER
  • 10.11 Vitalograph
  • 10.12 Vyaire Medical